Details of the Drug Reposition

General Information of This Drug (ID: DMI6HUW)

• Drug Name: Terbinafine (DMI6HUW)
• Synonyms: Bramazil; Lamasil; TerbiFoam; Terbina; Lamisil AT; Lamisil Tablet; Ternbinafine HCl; Lamasil (TN); Lamisil (TN); SF 86-327; Terbisil (TN); Zabel (TN); SF-86-327; Terbinafine (USAN/INN); Terbinafine [USAN:BAN:INN]; Lamisil, Terbinex, Corbinal, Zabel, Terbinafine; Terbinafine, SF-86-327, Lamisil, TBNF; (2E)-N,6,6-trimethyl-N-(1-naphthylmethyl)-2-hepten-4-yn-1-amine; (2E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine; (E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene methanamine; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine; (E)-N-(6,6-dimethyl-2-heptenynyl)-N-methyl-1-naphthalenementhamin hydrochloride
• Therapeutic Class: Antifungal Agents
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

3 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Tinea cruris	DIS5JC14	1F28.3	Approved	[1]
Fungal infection	DISGGVL1	1F29-1F2F	Approved	[2]
Tinea versicolor	DIS5VG35	1F2D.0	Approved	[1]

1 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Onychomycosis	DISE4C4D	EE12.1	Phase 2	[3]

References

• [1] Terbinafine FDA Label
• [2] Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. Ther Clin Risk Manag. 2005 Dec;1(4):299-306.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)